{"id":954388,"date":"2026-04-23T16:29:47","date_gmt":"2026-04-23T20:29:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/"},"modified":"2026-04-23T16:29:47","modified_gmt":"2026-04-23T20:29:47","slug":"trevi-therapeutics-to-participate-in-upcoming-may-events","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/","title":{"rendered":"Trevi Therapeutics to Participate in Upcoming May Events"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW HAVEN, Conn., April  23, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8FOQ492THrn4-uNBh_CjXNYq2auWoL5MQ6OektFArMMKSdzKRH3dfENHcdcTUyMy-uPcCBxpw0U1sTbH2L3iGXxTjrYnbeuoR8SqU8q36XWFKTMPK-ZbzMrmhiwKGhiB\" rel=\"nofollow\" target=\"_blank\"><u>Trevi Therapeutics, Inc.<\/u><\/a>\u00a0(Nasdaq: TRVI),\u00a0a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that senior management will participate in several upcoming events in May.<\/p>\n<p>\n        <strong><br \/>\n          <u>Trevi Therapeutics Investor and Analyst Day<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>May 7, 2026, Midtown New York, New York<br \/>10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussions<br \/><strong>Representatives:<\/strong> Trevi senior management will be joined by key opinion leaders in chronic cough in IPF\/ILD and RCC<br \/>To register for the virtual webcast, click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x8CNTsbd1x_05sBlrZCYN3y3oILg8dhB8ob5oAonjota1bn9hkZyD-chehBBYFzYu5XtsB1h_z8ALgWrBgOdPsyTVypYv0bbwjC_uLAbk-k=\" rel=\"nofollow\" target=\"_blank\">here<\/a>.\u00a0<\/p>\n<p>\n        <strong><br \/>\n          <u>Bank of America Global Healthcare Conference 2026<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>May 12-13, 2026, Las Vegas, Nevada <br \/><strong>Corporate Presentation:<\/strong> May 12, 5:15 p.m. to 5:30 p.m. PT (8:15 p.m. to 8:30 p.m. ET)<br \/><strong>Trevi Representatives:\u00a0<\/strong>Jennifer Good, President and CEO, and David Hastings, CFO<br \/>To register for the virtual webcast, click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x8CNTsbd1x_05sBlrZCYNwFnecMONimv7Ulv1zxWvxNQsnQE4k_H72_-qiv-BWeeqL7VSlA9oixVG04kLDbEfnzIwzRVpb4aXdEqwyc1YTupE7H-czUMiuXhbxfUHNZkXvgjYvnmQNGhswk1c7rUTQ==\" rel=\"nofollow\" target=\"_blank\">here<\/a>.\u00a0<\/p>\n<p>\n        <strong><br \/>\n          <u>Trevi Therapeutics: Data Highlights from Trevi\u2019s ATS 2026 Presentations<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>May 18, 2026, Orlando, Florida<br \/>11:30 a.m. to 1:15 p.m. ET<br \/><strong>Featuring:<\/strong> Philip Molyneaux, MD, PhD, Professor of Pulmonary Medicine at the Royal Brompton Hospital, and James Cassella, Ph.D., CDO, Trevi Therapeutics<br \/>This investor and analyst event will take place in-person, at the same time as the American Thoracic Society (ATS) 2026 International Conference. To register for the event, email <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oKyWazoJl0obct_HSGynRWLmFwQlgfgIV8QDUBTN3rEPN5F8dsJHOwFHENCFl08xqCY-LcH8MavFQlPZO-i3eg==\" rel=\"nofollow\" target=\"_blank\">IR@trevitx.com<\/a>.<\/p>\n<p>\n        <strong>About Trevi Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine extended-release for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF-related chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.<\/p>\n<p>Chronic\u202fcough\u202fin patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients&#8217; quality of life.<\/p>\n<p>RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting &gt;8\u2005weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip)\u202fand includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may\u202fimpact\u202fpatients physically, psychologically, and socially.<\/p>\n<p>Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.<\/p>\n<p>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C9AJEMmjZK2dMOswSyAqSOjB4qetbA97dokqNsRUKQuPViEaR1ltGhuxFMIQ5bxcHZUo4lLl9OVMQkgSoJTXa3GYvzlnALJqPo7nff6gjigCgxLit9iEXjYb3lcGo78V\" rel=\"nofollow\" target=\"_blank\"><u>www.TreviTherapeutics.com<\/u><\/a>\u00a0and follow Trevi on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FxNDgAt_jk5tSqfVljnUPKeMWe20fZyFDyWKNUylDtUu7vAwYs38B0MLedyIAsWJ9Yg68Tebs2ZOty37w0ZDbg==\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a>\u00a0(formerly Twitter) and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=coPdg9YAC7t6PHktEiCjgmPskHChwrSRspy9TTradACO_naezEaYU351MGIQ3OCPjvJBc_DLRUMqNKQAnzcAya0-SXIVNuBdp-j5PpzUO4rVejwmF4LUgOk9hkhtuY4f\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Jonathan Carlson <br \/>Trevi Therapeutics, Inc. <br \/>(203) 654 3286 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oKyWazoJl0obct_HSGynRb1OxBt5jdvGVBtp0DlguZQneL9dRgh-2FV6nLLi1LYI1mEp14f1qBzeMrGdd_Uq3A==\" rel=\"nofollow\" target=\"_blank\">IR@trevitx.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Rosalia Scampoli <br \/>914-815-1465 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sjvePckrTbdkjCRGHOlVvJIl33PwH0mL0JA0suIhYi3I96s5FpU0quzwmYQk8kqPlhoJo-nNKaQaoT6mddIoG4HC9fxlr9H0FDKHw8d1u6eUAH7Xhp1qNLnEOY7UiNHe\" rel=\"nofollow\" target=\"_blank\">rscampoli@marketcompr.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjAwNiM3NTUzMDQwIzIxMjUxMTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/N2I4NTU5ZjItN2JmMy00OGJhLThiOTAtYzg1MTJkMjE0Njg0LTExMzY2ODctMjAyNi0wNC0yMy1lbg==\/tiny\/Trevi-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI),\u00a0a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that senior management will participate in several upcoming events in May. Trevi Therapeutics Investor and Analyst Day May 7, 2026, Midtown New York, New York10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussionsRepresentatives: Trevi senior management will be joined by key opinion leaders in chronic cough in IPF\/ILD and RCCTo register for the virtual webcast, click here.\u00a0 Bank of America Global Healthcare Conference 2026 May 12-13, 2026, Las Vegas, Nevada Corporate Presentation: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Trevi Therapeutics to Participate in Upcoming May Events&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-954388","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trevi Therapeutics to Participate in Upcoming May Events - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trevi Therapeutics to Participate in Upcoming May Events - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI),\u00a0a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that senior management will participate in several upcoming events in May. Trevi Therapeutics Investor and Analyst Day May 7, 2026, Midtown New York, New York10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussionsRepresentatives: Trevi senior management will be joined by key opinion leaders in chronic cough in IPF\/ILD and RCCTo register for the virtual webcast, click here.\u00a0 Bank of America Global Healthcare Conference 2026 May 12-13, 2026, Las Vegas, Nevada Corporate Presentation: &hellip; Continue reading &quot;Trevi Therapeutics to Participate in Upcoming May Events&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T20:29:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjAwNiM3NTUzMDQwIzIxMjUxMTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-may-events\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-may-events\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trevi Therapeutics to Participate in Upcoming May Events\",\"datePublished\":\"2026-04-23T20:29:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-may-events\\\/\"},\"wordCount\":604,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-may-events\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NjAwNiM3NTUzMDQwIzIxMjUxMTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-may-events\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-may-events\\\/\",\"name\":\"Trevi Therapeutics to Participate in Upcoming May Events - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-may-events\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-may-events\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NjAwNiM3NTUzMDQwIzIxMjUxMTY=\",\"datePublished\":\"2026-04-23T20:29:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-may-events\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-may-events\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-may-events\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NjAwNiM3NTUzMDQwIzIxMjUxMTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NjAwNiM3NTUzMDQwIzIxMjUxMTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-may-events\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trevi Therapeutics to Participate in Upcoming May Events\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trevi Therapeutics to Participate in Upcoming May Events - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/","og_locale":"en_US","og_type":"article","og_title":"Trevi Therapeutics to Participate in Upcoming May Events - Market Newsdesk","og_description":"NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI),\u00a0a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that senior management will participate in several upcoming events in May. Trevi Therapeutics Investor and Analyst Day May 7, 2026, Midtown New York, New York10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussionsRepresentatives: Trevi senior management will be joined by key opinion leaders in chronic cough in IPF\/ILD and RCCTo register for the virtual webcast, click here.\u00a0 Bank of America Global Healthcare Conference 2026 May 12-13, 2026, Las Vegas, Nevada Corporate Presentation: &hellip; Continue reading \"Trevi Therapeutics to Participate in Upcoming May Events\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-23T20:29:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjAwNiM3NTUzMDQwIzIxMjUxMTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trevi Therapeutics to Participate in Upcoming May Events","datePublished":"2026-04-23T20:29:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/"},"wordCount":604,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjAwNiM3NTUzMDQwIzIxMjUxMTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/","name":"Trevi Therapeutics to Participate in Upcoming May Events - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjAwNiM3NTUzMDQwIzIxMjUxMTY=","datePublished":"2026-04-23T20:29:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjAwNiM3NTUzMDQwIzIxMjUxMTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NjAwNiM3NTUzMDQwIzIxMjUxMTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-may-events\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trevi Therapeutics to Participate in Upcoming May Events"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=954388"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954388\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=954388"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=954388"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=954388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}